Management of a feline gastric stromal cell tumour with toceranib phosphate: a case study

Abstract

Background A fifteen‐year old, female spayed domestic longhaired cat was presented for a routine vaccination during which an incidental abdominal mass was palpated. After further inquiry, occasional vomiting was reported to occur once every few weeks to months, associated with no other gastrointestinal signs. Case report Ultrasonography revealed a gastric mass. Histopathology and immunohistochemistry confirmed a CD117 positive, smooth muscle actin and desmin negative neoplasm, consistent with a gastrointestinal stromal cell tumour (GIST). Treatment was initiated with toceranib phosphate resulting in stable disease for over eighteen months, and the patient was still alive at the time of writing. Conclusion GISTs are rare in cats and this is the first report of medical management of feline GIST using toceranib.

Incidental diagnosis of a spindle cell type gastrointestinal stromal tumor in a dog with ethylene glycol intoxication

“…LMS tumors are negative for CD117, DOG1, and CD34, are consistently positive for SMA and/or desmin, and variably positive for S-100, and PGP 9.5. 7,9,11,12,14 Cases of GIST confirmed by immunostaining with CD117 have been reported in dogs [6][7][8][9][10][11][12]15 , cats [16][17][18] , horses 19,20 , ferrets 21 , rats 22 , and nonhuman primates. 4,23 Canine GISTs often express CD117, the surface receptor tyrosine-protein kinase KIT, encoded by the proto-oncogene c-KIT, similarly to hematopoietic stem cells and mast cells.…”

Gastrointestinal stromal tumour lacking mutations in the KIT and PDGFRA genes in a cat

“…Recently, there was a case report of a feline GIST that treated with toceranib phosphate where the cat survived for a long time without any adverse effects (McGregor et al . 2020). Although the present case was only treated with short‐term administration of TKIs, considering the generally good acceptabillity of TKIs in cats (Holtermann et al .…”

“…2011, Corless 2014, Suwa & Shimoda 2017, McGregor et al . 2020). In humans, GISTs frequently harbour gain‐of‐function mutations in the receptor tyrosine kinase genes, either the KIT gene or platelet‐derived growth factor receptor‐alpha ( PDGFRA ) gene, suggesting that these mutations lead to tumour development (Hirota et al .…”

A case with feline restrictive orbital myofibroblastic sarcoma treated with toceranib as adjuvant chemotherapy

“…[11][12][13] Toceranib, which is one of the molecular target drugs, is a tyrosine kinase receptor inhibitor and has been shown to inhibit KIT, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor. [14][15][16] Clinical use of toceranib in cats for the treatment of mast cell tumors 17,18 , adenocarcinoma 19,20 , gastrointestinal stromal tumor 21 , pancreatic carcinoma 22 , mammary carcinoma 23 , squamous cell carcinoma [24][25][26] , and feline injection site-associated sarcomas (FISS) 27 has been reported. However, the number of these reports in cats is fewer compared with that in dogs.…”